Key Market Indicator:
Stock market news: In short news style a la Twitter/X. Everything that is relevant - at a glance. The entry page for the informed investor. Compact, worth knowing and always up to date. Directly from the IR departments of the companies.
US80105B1017
Tue, 17.05.2022
Sangui BioTech International Inc.
Sangui BioTech:
- Significant increase in sales in the first nine months of the year
- Further reduction of the operating loss
Hamburg, May 17 2022: In the first nine months of fiscal year 2022 (to 30/06/2022) Sangui BioTech International Inc. achieved revenues from royalty income of USD 58,686. In the same period of the previous year the c [ … ]
Wed, 16.02.2022
Sangui BioTech International Inc.
Sangui BioTech:
- Significant increase in sales in the first half of the year
- Further reduction of the operating loss
Hamburg, February 16 2022: In the first six months of fiscal year 2022 (to 30/06/2022) Sangui BioTech International Inc. achieved revenues from royalty income of USD 40,732. In the same period of the previous year the compara [ … ]
Mon, 15.11.2021
Sangui BioTech International Inc.
Sangui BioTech:
- Sales of USD 18,560 in first quarter
- Reduction of the operating loss
Hamburg, November 15, 2021: In the first three months of fiscal year 2022 (to 30/06/2022) Sangui BioTech International Inc. achieved revenues from royalty income of USD 18,560. In the same period of the previous year the comparable revenue amounted to [ … ]
Thu, 21.10.2021
Sangui BioTech International Inc.
Sangui BioTech:
- Granulox is awarded the prestigious Prix Galien
Hamburg, October 21, 2021: The wound spray Granulox developed by Sangui and licensed to Mölnlycke Health Care GmbH was awarded the Prix Galien for the best medical product of 2020 in Belgium and Luxembourg. The Prix Galien is awarded annually. The awards were created in Franc [ … ]
Wed, 29.09.2021
Sangui BioTech International Inc.
Sangui BioTech:
- Sales of USD 65,582 in fiscal year 2021
- Reduction of the operating loss
Hamburg, September, 29 2021: In the fiscal year 2021 (01/07/2020 to 30/06/2021) Sangui BioTech International, Inc. achieved revenues from royalty income and product sales of USD 65,582. In the same period of the previous year the comparable revenue am [ … ]
Tue, 11.05.2021
Sangui BioTech International Inc.
Sangui BioTech:
- Granulox(R) - Follow up
Hamburg, May, 11 2021: With this letter we would like to briefly summarize the events since the acquisition of Sastomed GmbH by the Mölnlycke Health Care Group and point out the latest developments in the Granulox(R) wound spray.
The acquisition of SastoMed GmbH by the Mölnlycke Health Care Group at [ … ]
Mon, 10.05.2021
Sangui BioTech International Inc.
Sangui BioTech:
- Significant increase in sales in the first nine months
- Reduction of operating loss
Hamburg, May, 10 2021: In the first nine month of fiscal year 2021 (to 30/06/2021) Sangui BioTech International Inc. achieved revenues from royalty income of USD 51,754. In the same period of the previous year the comparable revenue amou [ … ]
Mon, 16.11.2020
Sangui BioTech International Inc.
Sangui BioTech:
- Significant increase in sales in the first quarter
- Reduction of operating loss
Hamburg, November, 16 2020: In the first three months of fiscal year 2021 (to 30/06/2021) Sangui BioTech International Inc. achieved revenues from royalty income of USD 19,880. In the same period of the previous year the comparable revenue a [ … ]
Thu, 01.10.2020
Sangui BioTech International Inc.
Sangui BioTech:- Sales of USD 28,915 in fiscal year 2020
Hamburg, October, 01, 2020: In the fiscal year 2020 (01/07/2019 to 30/06/2020) Sangui BioTech International, Inc. achieved revenues from royalty income and product sales of USD 28,915. In the same period of the previous year the comparable revenue amounted to USD 88,001. Due to decreased [ … ]